Purchase Order 75F40126P00095
Award Date 6/25/26
Potential Completion Date 8/24/27
Potential Value $53K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Irvine, CA 92612, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Food and Drug Administration (FDA) awarded a purchase order to Illumina, Inc. for an Illumina MiSeq i100Plus Sequencing System with a ceiling value of $97,054. The contract, which carries no set-aside designation, was awarded on September 18, 2025, with an ultimate completion date of October 20, 2025. The MiSeq i100Plus is an advanced DNA and RNA sequencing instrument that enables genomic analysis and research applications. Performance will take place at Illumina's San Diego, California...
- The Food and Drug Administration awarded a firm fixed price purchase order valued at $534,536 to Illumina, Inc., a San Diego-based biotechnology company specializing in genomic sequencing technologies, for one Illumina NextSeq 2000 Sequencer with post-warranty correction and remedial repair services. The contract, awarded on August 17, 2023, with an ultimate completion date of December 11, 2028, was issued under a combined synopsis/solicitation posted in May 2023. The sequencer will be delivered...
- The Food and Drug Administration awarded a $233.7K firm fixed-price purchase order to Illumina, Inc. for an Illumina NextSeq 2000 Sequencing System plus one option year of post-warranty maintenance. The award was issued on June 17, 2024, with an ultimate completion date of July 23, 2026. The equipment will be delivered to and maintained at the FDA's National Center for Toxicological Research in Jefferson, Arkansas, though the place of performance is listed as Singapore. No set-aside...
- The Food and Drug Administration awarded a $996,000 firm fixed-price delivery order to Illumina, Inc. for a MiSeq Sequencer and associated reagents on September 15, 2014, with an ultimate completion date of September 13, 2017. The award was issued to the San Diego-based biotechnology company without set-aside designation, reflecting Illumina's specialized position as the primary provider of next-generation DNA and RNA sequencing technologies to federal agencies. The delivery order procures...
- The Department of Health and Human Services Food and Drug Administration awarded a $19,283.10 firm fixed price purchase order to Illumina, Inc. to provide Illumina ISEQ 100 Systems. The ISEQ 100 Systems will be used for quality control and rebalancing of samples in sample pools. The systems are compatible with Illumina's library preparation kits and provide fast, cost-effective small-scale runs. The place of performance is Illumina's facilities in San Diego, California, and the period of...
- The Food and Drug Administration awarded a delivery order valued at $81,810 to Illumina, Inc. for a MiSeq instrument on March 16, 2015, with completion scheduled for September 13, 2017. This firm fixed-price delivery order, placed without set-aside designation, procures one of Illumina's established DNA sequencing platforms commonly used in genomic research and diagnostic applications. The MiSeq system is a mid-throughput sequencing instrument suitable for targeted sequencing projects, microbial...
- This firm fixed-price purchase order was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to provide a diagnostic check and system upgrades for the MiSeq Whole Genome Sequencer at six FDA laboratories. The $84,733.20 contract has a completion date of December 31, 2022 and was sole-sourced to Illumina due to the proprietary nature of the MiSeq technology. Illumina has previously provided sequencing systems,...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the procurement of the MiSeq whole genome sequencing instrument, a genome sequencer, with a ceiling value of $166,207.78 and a period of performance through June 30, 2029. The contract is not set aside for any specific business designation. Illumina holds multiple federal...
- The Food and Drug Administration awarded a $534,031 firm fixed-price purchase order to Illumina, Inc. for one Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System. This was a sole source award to the San Diego-based biotechnology company, with no set-aside designation applied. The equipment will be delivered to the FDA's facility in Silver Spring, Maryland, with a completion date of April 17, 2025. The Division of Applied Regulatory Science selected this system to enhance...
- The Department of Health and Human Services Food and Drug Administration awarded a $287,793 firm fixed price definitive contract to Illumina, Inc. to deliver three genome sequencers or equivalent solutions. The solicitation requested quotes for genome sequencers to be used by FDA regulatory laboratories for analyzing medical products and food samples. Illumina will provide the equipment within 90 days of award along with one year of warranty coverage, monthly status reports, and training....